EDIT
Editas Medicine Inc

17,121
Mkt Cap
$253.81M
Volume
1.88M
52W High
$4.54
52W Low
$0.9101
PE Ratio
-1.09
EDIT Fundamentals
Price
$2.59
Prev Close
$2.60
Open
$2.59
50D MA
$3.05
Beta
2.02
Avg. Volume
1.71M
EPS (Annual)
-$2.88
P/B
18.02
Rev/Employee
$131,357.72
Loading...
Loading...
News
all
press releases
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given an average rating of "Hold" by the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities...
MarketBeat·3d ago
News Placeholder
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given an average rating of "Hold" by the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities...
MarketBeat·3d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold...
MarketBeat·6d ago
News Placeholder
Insider Selling: Editas Medicine (NASDAQ:EDIT) CEO Sells 5,603 Shares of Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of...
MarketBeat·6d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving Average - Time to Sell?
Editas Medicine (NASDAQ:EDIT) Shares Cross Below Fifty Day Moving Average - Should You Sell...
MarketBeat·7d ago
News Placeholder
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
Zacks·16d ago
News Placeholder
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
Zacks·16d ago
News Placeholder
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
Zacks·20d ago
News Placeholder
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
Zacks·21d ago

Latest EDIT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.